JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 32 No. 1 27-30
© 1991 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huysmans, D. A.
Right arrow Articles by Kloppenborg, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huysmans, D. A.
Right arrow Articles by Kloppenborg, P. W.

Long-term Follow-up in Toxic Solitary Autonomous Thyroid Nodules Treated with Radioactive Iodine

Dyde A. Huysmans, Frans H. Corstens and Peter W. Kloppenborg

Departments of Nuclear Medicine and Medicine and Division of Endocrinology University Hospital Nijmegen, Nijmegen, The Netherlands

Correspondence: For reprints contact: Frans Corstens, M D, Dept. of Nuclear Medicine, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

ABSTRACT

The long-term effects of radioiodine treatment on thyroid function in patients with a toxic solitary autonomous thyroid nodule were evaluated. Fifty-two patients received a therapeutic dose of 20 mCi of iodine-131 (131I). Duration of follow-up was 10 ± 4 yr. Follow-up data included a biochemical evaluation of thyroid function. The failure rate (recurrent hyperthyroidism) was 2%. The incidence of hypothyroidism was 6% and was not related to the dose per gram of nodular tissue. Oral administration of 20 mCi of radioiodine is a simple and highly effective method for the treatment of patients with a toxic autonomous thyroid nodule. The risk of development of hypothyroidism is low if extranodular uptake of 131I is prevented. This can be achieved by not treating euthyroid patients, by no longer using injections of exogenous thyroid stimulating hormone in the diagnostic work-up of the patients and by always performing radioiodine imaging shortly before treatment.




This article has been cited by other articles:


Home page
JNMHome page
A. Iagaru and I. R. McDougall
Treatment of Thyrotoxicosis
J. Nucl. Med., March 1, 2007; 48(3): 379 - 389.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Zingrillo, S. Modoni, M. Conte, V. Frusciante, and V. Trischitta
Percutaneous Ethanol Injection plus Radioiodine Versus Radioiodine Alone in the Treatment of Large Toxic Thyroid Nodules
J. Nucl. Med., February 1, 2003; 44(2): 207 - 210.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
B. Nygaard, L. Hegedus, P. Ulriksen, K. G. Nielsen, and J. M. Hansen
Radioiodine Therapy for Multinodular Toxic Goiter
Arch Intern Med, June 28, 1999; 159(12): 1364 - 1368.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1991 by the Society of Nuclear Medicine.